Skip to main content

Physical, Social, and Psychological Consequences of Treatment for Hepatitis C

A Community-Based Evaluation of Patient-Reported Outcomes

The Patient - Patient-Centered Outcomes Research volume 6, pages 23–34 (2013)Cite this article

Abstract

Background

Hepatitis C virus (HCV) antiviral therapy entails a long treatment course, as well as significant side effects that can lead to medication non-adherence and premature termination of treatment. Few large studies have comprehensively examined patient perspectives on the treatment experience, particularly the social and personal effects.

Objective

We sought to understand how a diverse group of patients’ lives were affected during HCV treatment, and to obtain suggestions about how to better support patients during treatment.

Methods

On average, 13 months after therapy we interviewed by telephone a consecutive sample of 200 patients treated for hepatitis C with ribavirin and pegylated interferon in a comprehensive, integrated health plan in the years 2008–2010. Mixed (quantitative and qualitative) survey methods were used.

Results

The response rate was 68.9 %. Mean age at treatment was 51 years; 63.0 % were men; and Black, Hispanic, Asian, and White non-Hispanic racial/ethnic groups were similarly represented. Patients whose treatment was managed by nurses or clinical pharmacists (vs. physicians) were more likely to report their providers as being part of their support system (83.5 % vs. 58.9 %; p < 0.001). Most patients reported flu-like symptoms (93.5 %) and psychiatric problems (84.5 %), and 42.5 % reported side effects lasted up to 6 months after treatment. Black patients reported discontinuing treatment prematurely due to side effects more often than non-Blacks (29.4 % vs. 12.1 %; p < 0.001). Physical side effects (69.5 % of patients), psychiatric issues (43.5 %), and employment (27.4 %) were ranked among the three most difficult challenges. Patients desired help in anticipating and arranging work modifications during treatment. Most patients rated peer support, nutritional guidance, and weekly provider contact by telephone as potentially helpful resources for future patients undergoing HCV treatment.

Conclusions

Patient perspectives can help formulate and refine HCV treatment support programs. Effective support programs for diverse populations are crucial as the complexities and costs of HCV treatment increase. The call for greater support from peers, providers, and employers demands new systems such as patient-centered care teams.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. World Health Organization. Prevention and control of viral hepatitis infection: framework for global action. Geneva: World Health Organization; 2012.

    Google Scholar 

  2. Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, D.C.: The National Academies Press; 2010.

    Google Scholar 

  3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.

    PubMed  Article  CAS  Google Scholar 

  4. Bell BP, Manos MM, Zaman A, et al. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol. 2008;103:2727–36 (quiz 2737).

    Google Scholar 

  5. Manos MM, Leyden WA, Murphy RC, et al. Limitations of conventionally derived chronic liver disease mortality rates: results of a comprehensive assessment. Hepatology. 2008;47:1150–7.

    PubMed  Article  Google Scholar 

  6. Wise M, Bialek S, Finelli L, et al. Changing trends in hepatitis C-related mortality in the United States, 1995–2004. Hepatology. 2008;47:1128–35.

    PubMed  Article  Google Scholar 

  7. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.

    PubMed  Article  Google Scholar 

  8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.

    PubMed  Article  CAS  Google Scholar 

  9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.

    PubMed  Article  CAS  Google Scholar 

  10. Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702–8.

    PubMed  Article  CAS  Google Scholar 

  11. Hepburn MJ, Hepburn LM, Cantu NS, et al. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med. 2004;117:163–8.

    PubMed  Article  CAS  Google Scholar 

  12. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265–71.

    PubMed  Article  CAS  Google Scholar 

  13. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.

    PubMed  Article  CAS  Google Scholar 

  14. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology. 2010;139:1865–76.

    PubMed  Article  CAS  Google Scholar 

  15. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–9.

    PubMed  Article  CAS  Google Scholar 

  16. Rodis JL, Kibbe P. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs. 2010;33:368–73.

    PubMed  Article  Google Scholar 

  17. Fraenkel L, McGraw S, Wongcharatrawee S, et al. Patients’ experiences related to anti-viral treatment for hepatitis C. Patient Educ Couns. 2006;62:148–55.

    PubMed  Article  Google Scholar 

  18. Taylor-Young P, Hildebrandt E. The multidimensional burden of hepatitis C and its treatment: a case study. Gastroenterol Nurs. 2009;32:180–7.

    PubMed  Article  Google Scholar 

  19. McNally S, Temple-Smith M, Sievert W, et al. Now, later or never? Challenges associated with hepatitis C treatment. Aust N Z J Publ Health. 2006;30:422–7.

    Article  CAS  Google Scholar 

  20. Kinder M. The lived experience of treatment for hepatitis C. Gastroenterol Nurs. 2009;32:401–8.

    PubMed  Article  Google Scholar 

  21. Hopwood M, Treloar C. The experience of interferon-based treatments for hepatitis C infection. Qual Health Res. 2005;15:635–46.

    PubMed  Article  Google Scholar 

  22. Grogan A, Timmins F. Patients’ perceptions of information and support received from the nurse specialist during HCV treatment. J Clin Nurs. 2010;19:2869–78.

    PubMed  Article  Google Scholar 

  23. Sgorbini M, O’Brien L, Jackson D. Living with hepatitis C and treatment: the personal experiences of patients. J Clin Nurs. 2009;18:2282–91.

    PubMed  Article  Google Scholar 

  24. Gordon N. Similarity of the Adult Kaiser Permanente Membership in Northern California to the insured and general population in Northern California: statistics from the 2007 California Health Interview Survey. In: Internal report. Oakland (CA): Kaiser Permanente Division of Research; 2012.

  25. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Publ Health. 1992;82:703–10.

    Article  CAS  Google Scholar 

  26. Lopez M, Moreno L, Dosal A, et al. Interferon and the fear of needles: a case report. Gastroenterol Nurs. 2011;34:384–8.

    PubMed  Article  Google Scholar 

  27. Fontana RJ, Bieliauskas LA, Lindsay KL, et al. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology. 2007;45:1154–63.

    PubMed  Article  CAS  Google Scholar 

  28. Grogan A, Timmins F. Side effects of treatment in patients with hepatitis C: implications for nurse specialist practice. Aust J Adv Nurs. 2009;27:70–7.

    Google Scholar 

  29. Chang SC, Ko WS, Wu SS, et al. Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy. J Formos Med Assoc. 2008;107:454–62.

    PubMed  Article  Google Scholar 

  30. Cormier M. The role of hepatitis C support groups. Gastroenterol Nurs. 2005;28(3 Suppl):S4–9.

    PubMed  Article  Google Scholar 

  31. Jessop AB, Cohen C, Burke MM, et al. Hepatitis support groups: meeting the information and support needs of hepatitis patients. Gastroenterol Nurs. 2004;27:163–9.

    PubMed  Article  Google Scholar 

  32. Galindo L, Maginnis T, Wallace G, et al. Education by peers is the key to success. Int J Drug Policy. 2007;18:411–6.

    PubMed  Article  Google Scholar 

  33. Blasiole JA, Shinkunas L, Labrecque DR, et al. Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol. 2006;12:4665–72.

    PubMed  Google Scholar 

  34. Zickmund S, Ho EY, Masuda M, et al. “They treated me like a leper”: stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003;18:835–44.

    PubMed  Article  Google Scholar 

  35. Perrillo R, Rothstein KD, Rubin R, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat. 2004;11:157–65.

    PubMed  Article  CAS  Google Scholar 

  36. Su J, Brook RA, Kleinman NL, et al. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010;52:436–42.

    PubMed  Article  Google Scholar 

  37. DiBonaventura M, Wagner JS, Yuan Y, et al. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ. 2011;14:253–61.

    PubMed  Article  Google Scholar 

  38. Silveira MJ, Given CW, Cease KB, et al. Cancer carepartners: improving patients’ symptom management by engaging informal caregivers. BMC Palliat Care. 2011;10:21.

    PubMed  Article  Google Scholar 

  39. Zickmund S, Hillis SL, Barnett MJ, et al. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology. 2004;39:999–1007.

    PubMed  Article  Google Scholar 

  40. Gujral H, Viscomi C, Collantes R. The role of physician extenders in managing patients with chronic hepatitis C. Cleve Clin J Med. 2004;71(Suppl. 3):S33–7.

    PubMed  Article  Google Scholar 

  41. Smith JP, Dong MH, Kaunitz JD. Evaluation of a pharmacist-managed hepatitis C care clinic. Am J Health Syst Pharm. 2007;64:632–6.

    PubMed  Article  Google Scholar 

  42. Smith JP. Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events. Pharmacotherapy. 2008;28:1151–61.

    PubMed  Article  CAS  Google Scholar 

  43. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101:2254–62.

    PubMed  Article  Google Scholar 

  44. Silberbogen AK, Ulloa E, Mori DL, et al. A telehealth intervention for veterans on antiviral treatment for the hepatitis C virus. Psychol Serv. 2012;9:163–73.

    PubMed  Article  Google Scholar 

  45. Ho SB, Groessl E, Dollarhide A, et al. Management of chronic hepatitis C in veterans: the potential of integrated care models. Am J Gastroenterol. 2008;103:1810–23.

    PubMed  Article  Google Scholar 

  46. Evon DM, Simpson K, Kixmiller S, et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol. 2011;106:1777–86.

    PubMed  Article  CAS  Google Scholar 

  47. Yee HS, Chang MF, Pocha C, et al. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012;107:669–89 (quiz 690).

    Google Scholar 

  48. Sharma P, Lok AS. Interferon-free treatment regimens for hepatitis C: are we there yet? Gastroenterology. 2011;141:1963–7.

    PubMed  Article  Google Scholar 

  49. Poordad F, Chee GM. Interferon free hepatitis C treatment regimens: the beginning of another era. Curr Gastroenterol Rep. 2012;14:74–7.

    PubMed  Article  Google Scholar 

  50. Horberg MA, Hurley LB, Towner WJ, et al. Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2012;60:183–90.

    PubMed  Article  Google Scholar 

Download references

Acknowledgments

This study was supported by The Permanente Medical Group. Dr. Ho was supported by NIH T32 DK060414. We appreciate helpful suggestions from Drs. Carol Somkin, Douglas Corley, and Theodore Levin. We thank the many KPNC HCV treatment providers for their input in designing the interview. Special thanks to Dr. Philip Madvig for his interest in this work and subsequent efforts to bring the results into clinical practice. Most importantly, we thank the patients who generously participated in the PATH-C Study and shared their experiences so openly.

Conflicts of Interest

The authors have no conflicts of interest that are directly relevant to the content of this article

Author Contributions

MM and RM were responsible for study and survey design. RM conducted all patient recruitment and interviews. VS retrieved and analyzed all medical record data and identified eligible patients. CH and RM performed qualitative and quantitative survey data analysis. MM led the project overall and was primarily responsible for manuscript preparation, with contributions from CH and RM. MM is the guarantor for the overall content of this article.

Author information

Authors and Affiliations

  1. Kaiser Permanente Division of Research, Viral Hepatitis Registry, 2000 Broadway, Oakland, CA, 94612, USA

    M. Michele Manos, Chanda K. Ho, Rosemary C. Murphy & Valentina A. Shvachko

  2. Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA

    Chanda K. Ho

Authors
  1. M. Michele Manos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chanda K. Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rosemary C. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valentina A. Shvachko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Michele Manos.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 350 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Manos, M.M., Ho, C.K., Murphy, R.C. et al. Physical, Social, and Psychological Consequences of Treatment for Hepatitis C. Patient 6, 23–34 (2013). https://doi.org/10.1007/s40271-013-0005-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40271-013-0005-4

Keywords

  • Sustain Virologic Response
  • Clinical Pharmacist
  • Treatment Provider
  • Health Plan Member
  • Physical Side Effect